中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月7日星期一
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (11): 67-70    
  妇幼医学 本期目录 | 过刊浏览 | 高级检索 |
抗凝治疗对复发性流产伴子宫动脉阻力指数增高患者血栓前状态和妊娠结局的影响
袁金兰1 罗琼秀2
1.江西省吉安市妇幼保健院孕产保健科,江西吉安 343099;
2.江西省吉安市妇幼保健院辅助生殖科,江西吉安 343099
Effect of anticoagulant therapy on prethrombotic state and pregnancy outcome in patients with recurrent abortion and increased uterine artery resistance index
YUAN Jinlan1 LUO Qiongxiu2
1.Department of Pregnancy and Maternity Health,Ji′an Maternal and Child Health Hospital,Jiangxi Province,Ji′an 343099,China;
2.Department of Assisted reproduction,Ji′an Maternal and Child Health Hospital,Jiangxi Province,Ji′an 343099,China
全文: PDF (569 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨抗凝治疗对复发性流产伴子宫动脉阻力指数增高患者血栓前状态和妊娠结局的影响。方法 选取吉安市妇幼保健院2020年1月至12月收治的120 例复发性流产伴子宫动脉阻力指数增高患者作为研究对象,按照随机数字表法分为观察组和对照组,各60 例。所有患者均在阴道彩超提示宫内早早孕(孕5 周内)后开始用药。对照组给予地屈孕酮片、维生素E 胶囊治疗,观察组在对照组基础上加用低分子肝素钙治疗。比较两组患者治疗前后阻力指数(RI)变化、血栓前状态指标[D-二聚体(DD)、凝血酶时间(TT)、抗凝血酶Ⅲ(ATⅢ)活性]和妊娠活产率。结果 观察组治疗后RI 低于对照组,差异有统计学意义(P<0.05)。观察组治疗后DD 低于对照组,TT 和ATⅢ均高于对照组,差异有统计学意义(P<0.05)。观察组活产率高于对照组,差异有统计学意义(P<0.05)。结论 抗凝治疗可有效降低复发性流产伴子宫动脉阻力指数增高患者的RI,改善血栓前状态指标和妊娠妊娠结局。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 抗凝治疗复发性流产子宫动脉阻力指数血栓前状态指标妊娠结局    
Abstract:Objective To investigate the effect of anticoagulant therapy on prethrombotic state and pregnancy outcome in patients with recurrent abortion and increased uterine artery resistance index.Methods A total of 120 patients with recurrent miscarriage with increased uterine artery resistance index admitted to Ji′an Maternity and Child Health Hospital from January to December 2020 were selected as research objects.They were divided into observation group and control group according to random number table method,with 60 cases in each group,all patients began to use drugs after vaginal color Doppler ultrasound prompts early intrauterine pregnancy(within 5 weeks of pregnancy).The control group was given Dydrogesterone Tablets and Vitamin E Capsules.The observation group was treated with Low-molecular-weight Heparin Calcium on the basis of the control group.The changes of resistance index(RI),prethrombotic state indexes(D-dimer[DD],thrombin time[TT],antithrombin Ⅲ[ATⅢ]activity)and pregnancy activity rate were compared between the two groups before and after treatment.Results The RI score of the observation group after treatment was lower than that of the control group,and the difference was statistically significant(P<0.05).After treatment,DD in the observation group was lower than that in the control group,and TT and ATⅢwere higher than those in the control group,and the differences were statistically significant(P<0.05).The live birth rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion Anticoagulant therapy can effectively reduce RI,improve prethrombotic state and pregnancy outcome in patients with recurrent abortion and increased uterine artery resistance index.
Key wordsAnticoagulant therapy    Recurrent abortion    Uterine artery resistance index    Prethrombotic state index    Pregnancy outcome
收稿日期: 2021-10-12     
基金资助:江西省卫生健康委科技计划项目(202140976)
引用本文:   
袁金兰;罗琼秀. 抗凝治疗对复发性流产伴子宫动脉阻力指数增高患者血栓前状态和妊娠结局的影响[J]. 中国当代医药, 2022, 29(11): 67-70.
YUAN Jinlan1 LUO Qiongxiu2. Effect of anticoagulant therapy on prethrombotic state and pregnancy outcome in patients with recurrent abortion and increased uterine artery resistance index. 中国当代医药, 2022, 29(11): 67-70.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I11/67
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载